Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | ACE | P12821 | 2/20 | 0.59 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.55 |
| ▸ | ECE1 | P42892 | 6/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MPO | P05164 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | CCKBR | P32239 | 2/20 | 0.53 |
| ▸ | CCKAR | P32238 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051830 | 0.97 | CTSC (0.71) | CTSCMEN1KMT2AACEERAP2 | |
| SCHEMBL30052005 | 0.96 | CTSC (0.69) | CTSCMEN1KMT2AACEERAP2 | |
| SCHEMBL30052009 | 0.96 | CTSC (0.64) | CTSCMEN1KMT2AACEERAP2 | |
| SCHEMBL7049417 | 0.95 | CTSC (0.73) | CTSCMEN1KMT2AACEECE1 | |
| SCHEMBL13154782 | 0.95 | CTSC (0.73) | CTSCMEN1KMT2AACEECE1 | |
| SCHEMBL7048700 | 0.95 | CTSC (0.73) | CTSCMEN1KMT2AACEECE1 | |
| SCHEMBL7048698 | 0.95 | CTSC (0.73) | CTSCMEN1KMT2AACEECE1 | |
| SCHEMBL30051525 | 0.93 | CTSC (0.66) | CTSCMEN1KMT2AACEERAP2 | |
| SCHEMBL30051544 | 0.93 | CTSC (0.66) | CTSCMEN1KMT2AACEERAP2 | |
| SCHEMBL30053185 | 0.93 | CTSC (0.61) | CTSCMEN1KMT2AACEALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | CTSC 131/4885MEN1 1217/4885KMT2A 1801/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | CTSC 37/4885MEN1 1147/4885KMT2A 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.